Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets.
AKI-to-CKD transition
YAP/TAZ
acute kidney injury
chronic kidney disease
hippo signaling
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
03
2023
revised:
19
04
2023
accepted:
26
05
2023
medline:
24
7
2023
pubmed:
3
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
Acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition is a slow but persistent progression toward end-stage kidney disease. Earlier reports have shown that Hippo components, such as Yes-associated protein (YAP) and its homolog Transcriptional coactivator with PDZ-binding motif (TAZ), regulate inflammation and fibrogenesis during the AKI-to-CKD transition. Notably, the roles and mechanisms of Hippo components vary during AKI, AKI-to-CKD transition, and CKD. Hence, it is important to understand these roles in detail. This review addresses the potential of Hippo regulators or components as future therapeutic targets for halting the AKI-to-CKD transition.
Identifiants
pubmed: 37268185
pii: S1359-6446(23)00165-4
doi: 10.1016/j.drudis.2023.103649
pii:
doi:
Substances chimiques
Transcription Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103649Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.